Autres langues Protagonist Therapeutics, Inc.

Actions

PTGX

US74366E1029

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 21/05/2024			Varia. 5j.	Varia. 1 janv.
31,71 ^USD	+1,44 %		+7,09 %	+38,29 %

07/05	Protagonist Therapeutics, Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI
03/04	Un initié de Protagonist Therapeutics a vendu des actions d'une valeur de 707 750 $, selon un récent dépôt auprès de la SEC	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Protagonist Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	07/05
Protagonist Therapeutics: Q1 Earnings Snapshot	07/05
Protagonist Therapeutics Insider Sold Shares Worth $707,750, According to a Recent SEC Filing	03/04
Protagonist Therapeutics Provides Update on VERIFY Patient Enrollment and Timing of Top-line Data	27/03
Protagonist Therapeutics, Inc. Provides Update on Verify Patient Enrollment and Timing of Top-Line Data	26/03
Protagonist Therapeutics Announces Closing of Worldwide Rusfertide License and Collaboration Agreement with Takeda	18/03
Protagonist Therapeutics' Potential Plaque Psoriasis Drug Shows High Skin Clearance Rates in Phase 2B Study	11/03
Protagonist Therapeutics, Inc. Announces Late-Breaking Presentation At the American Academy of Dermatology 2024 Annual Meeting with Positive Results from the Phase 2B Frontier 2 Long-Term Extension Study Evaluating JNJ-2113, the First and Only Investigational Targeted Oral Peptide Designed to Block the IL-23 Receptor, for Adult Patients with Moderate-To-Severe Plaque Psoriasis	11/03
Protagonist Therapeutics Insider Sold Shares Worth $948,600, According to a Recent SEC Filing	04/03
Protagonist Therapeutics Insider Sold Shares Worth $406,637, According to a Recent SEC Filing	04/03
Protagonist Therapeutics Insider Sold Shares Worth $764,365, According to a Recent SEC Filing	04/03
Protagonist Therapeutics: Q4 Earnings Snapshot	27/02
Protagonist Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27/02
Protagonist Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	27/02
Protagonist Therapeutics Shares Rise 5.6% on Licensing Deal With Takeda	01/02
Takeda and Protagonist Therapeutics, Inc. Enter into Worldwide License and Collaboration Agreement for Rusfertide, a Late-Stage Rare Hematology Asset	31/01
Protagonist Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare Talks 2024	30/01
Protagonist Therapeutics Insider Sold Shares Worth $1,506,000, According to a Recent SEC Filing	15/12
Protagonist Therapeutics Earns $10 Million Milestone Payment in Ulcerative Colitis Trial	13/12
Protagonist Reports 2-Year Follow Up Data from Rusfertide REVIVE Study at the ASH Annual Meeting Showing Durable Efficacy and No New Safety Signals	13/12

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Protagonist Therapeutics, Inc.

Actions

PTGX

US74366E1029

Autres langues

Filtres